Macrophage activation syndrome is a severe, potentially fatal inflammatory crisis in which the immune system turns on the body’s own tissues instead of fighting a threat. It belongs to a family of conditions called hemophagocytic lymphohistiocytosis (HLH), and it earns its own name because it typically strikes people who already have an autoimmune or autoinflammatory disease, most often systemic juvenile idiopathic arthritis (sJIA).1PubMed Central. Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis in Childhood Inflammatory Disorders: Diagnosis and Management What makes MAS so dangerous is its speed: a patient can go from looking like they have a routine disease flare to organ failure within days, and recognizing the difference is one of the hardest calls in rheumatology.
Where MAS Fits in the Bigger Picture
The term “macrophage activation syndrome” first appeared in a paper title in 1993, though cases matching the description had been showing up in the medical literature since at least the 1970s.2PubMed. The History of Macrophage Activation Syndrome in Autoimmune Diseases Rheumatologists coined the name to distinguish this specific situation from HLH more broadly. When HLH develops as a complication of an autoimmune disease, they call it MAS. When it occurs in other settings, such as after cancer treatment or a severe infection in someone without a known autoimmune condition, it usually goes by “secondary HLH.” The biology, however, is strikingly similar in both cases: immune cells go into overdrive, flood the bloodstream with inflammatory signals, and begin damaging organs.
There used to be a clean dividing line between “primary” HLH (caused by inherited genetic mutations, usually diagnosed in infancy) and “secondary” forms like MAS (triggered by infections, flares of autoimmune disease, or malignancies). That line has blurred. Researchers are finding that many people who develop MAS after an apparent trigger actually carry subtle mutations in the same genes responsible for primary HLH, suggesting they were genetically primed all along.3PubMed Central. Macrophage Activation Syndrome Versus Hemophagocytic Lymphohistiocytosis: A Diagnostic Dilemma in a Patient With Still’s Disease and Epstein-Barr Virus Viremia – Section: Discussion In practical terms, this means MAS is increasingly understood not as a purely acquired event but as the collision of a genetic vulnerability with an environmental spark.
What Goes Wrong Inside the Immune System
Under normal circumstances, when your immune system encounters an invader, natural killer (NK) cells and a subset of T cells called CD8 cells destroy infected cells and then wind down. The winding-down step is crucial. It depends on a molecular machinery that lets those killer cells release tiny packets of enzymes (called granules) that punch holes in their targets. If that machinery is defective, the target cells don’t die efficiently, and the killer cells keep signaling for reinforcements that never quite finish the job. The result is a runaway loop of inflammatory signaling, sometimes called a cytokine storm, that damages blood cell production, disrupts clotting, and starts shutting down organs.4PubMed. Genetic defects in cytolysis in macrophage activation syndrome
Macrophages, the large immune cells that give the syndrome its name, are central to the destruction. In MAS, activated macrophages invade the bone marrow, liver, spleen, and lymph nodes and begin engulfing blood cells, a phenomenon called hemophagocytosis. These rogue macrophages display a surface marker called CD163, a receptor that normally helps manage the oxidative stress caused by free iron. When hemophagocytosis ramps up and red blood cells are being consumed in large numbers, iron metabolism goes haywire, and ferritin levels in the blood skyrocket.5PubMed Central. Macrophage activation syndrome: advances towards understanding pathogenesis That ferritin spike turns out to be one of the most important clues doctors have for catching MAS early.
Who Gets It and What Sets It Off
MAS shows up most often in children and young adults with systemic juvenile idiopathic arthritis. In one cohort of sJIA patients, roughly a third developed MAS at some point during their disease.6Modern Rheumatology. The frequency of macrophage activation syndrome and disease course in systemic juvenile idiopathic arthritis That is a remarkably high rate for a complication that can be lethal. Adult-onset Still’s disease, the grown-up equivalent of sJIA, carries a similar risk. Systemic lupus erythematosus (SLE), Kawasaki disease, and other rheumatic conditions can also trigger MAS, though less commonly.
Infections are a major spark. Viruses in particular, including Epstein-Barr virus, cytomegalovirus, and influenza, can push a susceptible immune system over the edge.7PubMed Central. Macrophage Activation Syndrome in Viral Sepsis – Section: 1. Introduction Sometimes MAS appears as the very first sign that a person has an underlying autoimmune disease. In one reported case, a pregnant woman developed MAS triggered by parvovirus B19 infection, and it was only after the crisis that she was diagnosed with SLE.8PubMed Central. Life-Threatening Macrophage Activation Syndrome in Pregnancy: First Manifestation of SLE Induced by Parvovirus B19 The interplay between infection and autoimmune disease makes the clinical picture genuinely confusing: the infection can trigger MAS, and MAS can mask the infection, and both can look like a straightforward disease flare.
Medications occasionally play a role as well. Changes to immunosuppressive therapy, or even the initiation of biologic drugs that are meant to calm the immune system, have been associated with MAS episodes, although disentangling whether the drug or the underlying disease activity is the real culprit is often impossible.
The Genetic Angle
The distinction between inherited HLH and MAS used to seem straightforward: if you had two copies of a defective gene in the cell-killing pathway, you got primary HLH in infancy; if you didn’t, any HLH-like episode was “secondary.” But gene-sequencing studies have complicated that story. Patients who develop MAS later in life sometimes carry a single copy of a mutation in the same genes, or they carry combinations of milder variants across several genes in the cytolytic pathway.9PubMed. Genetic defects in cytolysis in macrophage activation syndrome These partial defects may not be enough to cause disease on their own but could lower the threshold at which an infection or autoimmune flare tips the immune system into crisis. This has real implications for families: siblings of a child who had MAS may benefit from genetic testing, even if they seem healthy.
How Doctors Recognize MAS
Catching MAS early is difficult because its initial symptoms overlap with a disease flare or an ordinary infection. High, unremitting fever is almost always present. The liver and spleen often enlarge. Blood counts drop, particularly platelets and white blood cells, because the overactive macrophages are literally eating them. Clotting becomes abnormal. Liver enzymes spike. The erythrocyte sedimentation rate, which is usually elevated during autoimmune inflammation, paradoxically falls in MAS because fibrinogen is being consumed by the clotting disorder.
A set of formal classification criteria published in 2016 by a collaboration between European and American rheumatology societies was developed specifically for MAS complicating sJIA. In validation studies, these criteria achieved a specificity of 0.99 and a sensitivity of 0.73, meaning they are excellent at ruling in MAS when present but miss roughly a quarter of cases.10PubMed. 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis Because missing a case can be fatal, clinicians often act on suspicion before criteria are formally met.
Ferritin as the Alarm Bell
Of all the lab markers, ferritin gets the most attention. In normal health, serum ferritin sits under a few hundred nanograms per milliliter. In MAS, levels frequently soar into the thousands or tens of thousands. Ferritin above 3,000 ng/mL should raise strong clinical suspicion for MAS or HLH.11PubMed Central. Update in Hyperferritinemic Syndromes: Recognition and Management – A Scoping Review – Section: Hemophagocytic lymphohistiocytosis (HLH) and Macrophage Activation Syndrome (MAS) Ferritin is not just a diagnostic clue; it also tracks how well treatment is working and signals prognosis. Even moderately elevated ferritin that is rising rapidly can indicate trouble ahead.12PubMed Central. Hyperferritinemia and Macrophage Activation Syndrome in Septic Shock: Recent Advances with a Pediatric Focus
A retrospective study of patients with ferritin above 10,000 found that HLH or MAS had been formally diagnosed in about 40% of them, but clinicians hadn’t even considered MAS as a possibility in nearly a quarter of the group. Overall mortality in that cohort was about 33%.13Annals of the Rheumatic Diseases. Highly Elevated Ferritin Levels Are Associated with Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome – Section: Results The implication is sobering: even when the lab numbers are screaming, the diagnosis is sometimes overlooked.
IL-18 and Other Emerging Biomarkers
Interleukin-18 (IL-18) has emerged as a particularly promising biomarker in patients with sJIA. Patients who went on to develop MAS had significantly higher IL-18 levels during active disease than those who did not, and levels above roughly 47,750 pg/mL were proposed as a cutoff for predicting MAS development.14PubMed. Interleukin-18 for predicting the development of macrophage activation syndrome in systemic juvenile idiopathic arthritis Separate work confirmed that patients with a history of MAS had IL-18 levels more than tenfold higher than those without, though IL-18 remained above normal in many sJIA patients regardless of MAS history.15Rheumatology. IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome – Section: Results IL-18 is not yet part of routine screening in most hospitals, but its ability to flag patients at high risk before they crash makes it an active area of research.
Interferon-gamma (IFN-γ) and its downstream marker CXCL9, along with soluble IL-2 receptor, are also tracked during treatment to gauge whether the inflammatory cascade is being suppressed. In trials of targeted therapy, rapid drops in CXCL9 and soluble IL-2 receptor correlated with clinical improvement.16Annals of the Rheumatic Diseases. Efficacy and safety of emapalumab in macrophage activation syndrome – Section: Results
Treatment Approaches
The first-line treatment for most cases of MAS is high-dose corticosteroids, typically pulse intravenous methylprednisolone. If the underlying autoimmune disease is not yet under control, cyclosporine is often added. For many patients, this combination is enough to halt the storm. The challenge arises when it isn’t.
Anakinra, a drug that blocks interleukin-1, has become a critical tool for corticosteroid-refractory MAS, especially in sJIA. Standard dosing runs about 1 to 2 mg per kilogram per day, but case reports describe effective rescue at dramatically higher doses, up to roughly six times the standard amount, without additional side effects.17Journal of Rheumatic Diseases and Treatment. Treatment of Refractory Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis with High Dose Anakinra – Section: Case Discussion Intravenous administration of anakinra has also been studied in children with MAS, with most patients showing improvements in ferritin, fibrinogen, platelet counts, and liver enzymes after treatment was started.18PubMed Central. Intravenous administration of anakinra in children with macrophage activation syndrome
Targeting Interferon-Gamma
Because IFN-γ is a central driver of the inflammatory loop in MAS, blocking it directly is a logical next step. Emapalumab, a monoclonal antibody against IFN-γ, was initially approved for primary HLH and has now shown early promise in MAS. In one reported case of adult-onset Still’s disease complicated by secondary MAS, emapalumab eliminated fevers and normalized all MAS-associated lab abnormalities.19PubMed Central. Successful treatment of secondary macrophage activation syndrome with emapalumab in a patient with newly diagnosed adult-onset Still’s disease: case report and review of the literature Larger trials have since been conducted, with results showing rapid neutralization of IFN-γ activity as measured by falling CXCL9 levels.20Annals of the Rheumatic Diseases. Efficacy and safety of emapalumab in macrophage activation syndrome – Section: Results
JAK Inhibitors as a Rescue Option
Ruxolitinib, a drug originally developed for blood cancers, blocks Janus kinases 1 and 2, which sit upstream of many of the inflammatory signals driving MAS. It has emerged as a potential therapy for refractory cases where standard treatments have failed.21PubMed Central. Efficacy and safety of ruxolitinib in adult patients with refractory rheumatic disease-associated macrophage activation syndrome Case reports describe patients with refractory HLH-MAS who experienced resolution of fevers, normalization of inflammatory markers, and recovery of organ function after ruxolitinib was added.22PubMed Central. Breaking the storm: ruxolitinib as a lifeline in refractory hemophagocytic lymphohistiocytosis with macrophage activation syndrome The evidence base is still thin, mostly case reports and small series, but for patients who are running out of options, ruxolitinib offers another mechanism of action to try.
Prognosis and What Drives Outcomes
Mortality in MAS varies widely depending on the population studied and how quickly treatment is started. In adults with autoimmune disease-associated MAS, one study reported that about 42% of patients died during follow-up, with older age and higher ferritin at diagnosis being the strongest predictors of death.23PubMed. Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: Analysis of 41 cases collected in 2 rheumatologic centers A larger, more recent Chinese cohort reported in-hospital mortality of about 15%, with very low platelet counts, severely elevated liver enzymes, nervous system involvement, and elevated procalcitonin all independently linked to death.24PubMed Central. Clinical characteristics and prognostic factors in adult macrophage activation syndrome: an observational study in a Chinese cohort – Section: Results The gap between these figures reflects differences in study design, disease mix, and era of treatment, but the consistent message is that MAS remains life-threatening, and outcomes depend heavily on early recognition and aggressive therapy.
Children with sJIA-associated MAS generally fare somewhat better than adults, in part because pediatric rheumatologists are trained to watch for it and because children tend to have fewer comorbidities. Still, even in pediatric centers, MAS is treated as an emergency. The trend over the past decade has been toward earlier and more aggressive intervention, which appears to be improving survival, though controlled trials are difficult to conduct in a disease this dangerous and this relatively rare.
When MAS Hides Inside Sepsis
One of the trickiest clinical problems is distinguishing MAS from severe sepsis, because the two conditions share many features: high fevers, organ failure, falling blood counts, abnormal clotting. Researchers have proposed the concept of “macrophage activation-like syndrome” (MALS) in septic patients. In two large cohorts totaling more than 5,000 patients with sepsis, roughly 4% met criteria for MALS, and those patients had significantly higher odds of dying within ten days compared to septic patients without MALS features.25PubMed Central. Macrophage Activation-Like Syndrome: A Distinct Entity Leading to Early Death in Sepsis – Section: Macrophage Activation-Like Syndrome in Sepsis: Does This Exist? Identifying this subset matters because the treatment is different: standard sepsis management focuses on antibiotics and supportive care, while MALS may benefit from immunomodulatory therapy to tamp down the inflammatory overshoot. The problem is that adding immunosuppression in someone with a raging infection is inherently risky, so getting the diagnosis right is critical.
MAS in Pregnancy
MAS during pregnancy is rare but carries extraordinary stakes for both the mother and the fetus. Pregnancy itself alters the immune system in ways that can unmask autoimmune disease, and viral infections like parvovirus B19 can trigger MAS in a previously healthy-appearing pregnant woman. In one documented case, treatment required intravenous immunoglobulin and corticosteroids, and when the patient’s condition deteriorated, the pregnancy had to be terminated to save her life. She subsequently required months of treatment including cyclophosphamide and mycophenolate mofetil for lupus nephritis that emerged in the aftermath.26PubMed Central. Life-Threatening Macrophage Activation Syndrome in Pregnancy: First Manifestation of SLE Induced by Parvovirus B19 The clinical decision-making in such cases is agonizing, and there are no large studies to guide it, only individual reports and expert consensus.
Why MAS Is Still Underdiagnosed
Despite growing awareness, MAS continues to be missed, sometimes with fatal consequences. Several factors contribute. The overlap with disease flares in rheumatic disease means that early MAS can look like “more of the same” until it suddenly isn’t. Outside of pediatric rheumatology, many physicians have limited experience with the condition. Ferritin is not always included in routine workups for acutely ill patients, and even when it is drawn, the significance of very high values may not register immediately. As the retrospective study of patients with ferritin above 10,000 showed, MAS was not even considered in nearly a quarter of cases.27Annals of the Rheumatic Diseases. Highly Elevated Ferritin Levels Are Associated with Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome – Section: Results
One practical step that advocates have pushed for is making ferritin a reflex order in any hospitalized patient with unexplained multiorgan dysfunction or persistent fever unresponsive to antibiotics. A ferritin level is cheap and fast, and while a high result has many possible explanations, it at least puts MAS on the radar. For patients already known to have sJIA, lupus, or Still’s disease, serial ferritin monitoring during flares is increasingly standard at specialized centers but far from universal.
Bone marrow biopsy, which can show hemophagocytosis directly under the microscope, was once considered nearly essential for diagnosis. It remains useful but is no longer thought to be required, in part because hemophagocytosis can be absent early in the course and present in conditions other than MAS. The current approach leans more on the pattern of lab abnormalities combined with clinical context than on any single test.